|
|
||||||||
Immunology Division, Department of Pediatrics, Faculty of Medicine, Université de Sherbrooke, Sherbrooke, Quebec, Canada
Glucocorticoids can down-regulate many inflammatory and immune
responses and constitute a powerful therapeutic tool in a number of
diseases. However, they have a somewhat paradoxical effect on
neutrophils, in that they prolong their survival. Because leukotriene
B4 (LTB4) can also extend neutrophil survival,
we proposed that glucocorticoids could prevent neutrophil apoptosis by
up-regulating their expression of the high-affinity LTB4
receptor (BLT1). Here we show that, indeed, dexamethasone (DEX)
up-regulates the steady-state levels of BLT1 mRNA in human neutrophils.
The effect was time and concentration dependent, being maximal at
4 h and at 10100 nM DEX. The effect was also dependent on
transcriptional activity, whereas BLT1 mRNA stability was not affected.
DEX-induced up-regulation of BLT1 expression was prevented by
pretreatment with the LTB4 antagonist LY255283. Moreover,
LTB4 itself up-regulated the expression of BLT1 mRNA. BLT1
protein expression on neutrophils exposed to DEX for 24 h was also
up-regulated 2- to 3-fold, and DEX-treated as well as
LTB4-treated cells showed enhanced responsiveness to
LTB4 in terms of intracellular Ca2+
mobilization and chemotaxis. Whereas DEX and LTB4 alone
decreased neutrophil apoptosis by
50%, neutrophils treated with
both LTB4 and DEX showed >90% survival at 24 h.
Moreover, BLT1 antagonists prevented the increased neutrophil survival
induced by DEX as well as by LTB4. Taken together, our
results suggest that DEX-induced up-regulation of BLT1 expression in
neutrophils may be one mechanism through which glucocorticoids can
prolong neutrophil survival, namely by enhancing cell responses to the
antiapoptotic effect of LTB4.
This article has been cited by other articles:
![]() |
M. Peters-Golden and W. R. Henderson Jr. Leukotrienes N. Engl. J. Med., November 1, 2007; 357(18): 1841 - 1854. [Full Text] [PDF] |
||||
![]() |
H. Qiu, A.-S. Johansson, M. Sjostrom, M. Wan, O. Schroder, J. Palmblad, and J. Z. Haeggstrom Differential induction of BLT receptor expression on human endothelial cells by lipopolysacharide, cytokines, and leukotriene B4 PNAS, May 2, 2006; 103(18): 6913 - 6918. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Pettersson, A. Sabirsh, J. Bristulf, K. Kidd-Ljunggren, B. Ljungberg, C. Owman, and U. Karlsson Pro- and anti-inflammatory substances modulate expression of the leukotriene B4 receptor, BLT1, in human monocytes J. Leukoc. Biol., June 1, 2005; 77(6): 1018 - 1025. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Gaudreault, C. Thompson, J. Stankova, and M. Rola-Pleszczynski Involvement of BLT1 Endocytosis and Yes Kinase Activation in Leukotriene B4-Induced Neutrophil Degranulation J. Immunol., March 15, 2005; 174(6): 3617 - 3625. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Back, H. Qiu, J. Z. Haeggstrom, and K. Sakata Leukotriene B4 is an indirectly acting vasoconstrictor in guinea pig aorta via an inducible type of BLT receptor Am J Physiol Heart Circ Physiol, July 1, 2004; 287(1): H419 - H424. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |